TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Acromegaly:~* Male or female patients ≥18 years of age~* Acromegaly currently treated with Sandostatin LAR~NET:~* Male or female patients ≥18 years of age~* Functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid syndrome (number of bowel movements and/or flushing)~* Currently treated with Sandostatin LAR for symptom control~Exclusion Criteria:~Acromegaly:~* Inadequate bone marrow function~* Abnormal coagulation or chronic treatment with warfarin or coumarin derivates~* Impaired liver, cardiac and/or renal function~* Known gallbladder, bile duct disease or pancreatitis~* Diabetes with poorly controlled blood glucose levels despite adequate therapy~* Hypothyroidisms not adequately treated~NET:~* Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma and small cell carcinoma~* Carcinoid syndrome refractory to treatment with conventional doses of somatostatin analogues (SSAs)~* Inadequate bone marrow function~* Abnormal coagulation or chronic treatment with warfarin or coumarin derivates~* Impaired liver, cardiac and/or renal function~* Known gallbladder, bile duct disease or pancreatitis~* Short-bowel syndrome~* Diabetics with poorly controlled blood glucose levels despite adequate therapy~* Hypothyroidism, not adequately treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAM2029 10 mg (NET) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
- CAM2029 20 mg (NET) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
- CAM2029 10 mg (Acromegaly) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
- CAM2029 20 mg (Acromegaly) (Type: EXPERIMENTAL): CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Venlafaxine ER in Recurrent Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Clinical diagnosis for recurrent major depression~Exclusion Criteria~* The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant~* Known hypersensitivity to venlafaxine or fluoxetine~* History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Treated with insulin for at least 12 months~* Either plan to become pregnant in the immediate future, willing to undertake pre pregnancy counselling, and has a screening HbA1c lesser than or equal to 12.0%, or~* Pregnant with normal singleton pregnancy, gestational age for at least 10 weeks at the time of randomisation, confirmed by ultrasound scan.~Exclusion Criteria:~* Previous birth of child with a major congenital malformation~* More than 2 previous multiple miscarriages or stillbirths~* Severe hyperemesis gravidarum, requiring hospitalisation, according to Investigator judgement~* Subjects being treated for infertility~* Proliferative retinopathy or maculopathy requiring acute treatment~* Drug or alcohol abuse~* Impaired renal, hepatic or cardiac function

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Attending 1 of 29 participating HIV clinics~* Confirmed HIV infection~* Age \> 15 years~Exclusion Criteria:~* Current active TB disease~* TB infection within 2 years~* Hepatitis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Subjects in clinics that have not received the intervention
- 2 (Type: EXPERIMENTAL): Subjects at clinics that have received the intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C (anti-HCV antibodies and detectable HCV-RNA).~* Genotype 1b infection~* Treatment-naïve and non-cirrhotic~Exclusion Criteria:~* HCV genotype or subtype other than GT1b.~* Any current or past clinical evidence of cirrhosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spanish cohort with HCV treated with DAA (Type: None): Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed perianal high-grade squamous intraepithelial lesions (HSIL) within the past 12 weeks~  * The perianal skin (i.e., perianus) is defined as extending radially 5 cm from the anal verge~ * Lesions must cover a surface area of ≥ 3 square centimeters~ * Lesions extending outside the perianus (e.g., vulvar lesions on the posterior perineum bordering the perianus) are allowed~* Serologic documentation of HIV infection AND meets 1 of the following criteria:~  * Has been on stable highly active anti-retroviral therapy (HAART) for ≥ 12 weeks prior to study entry~ * Has a CD4 count of \> 200/mm³ AND is not receiving anti-retroviral therapy OR is currently receiving a non-HAART\* anti-retroviral regimen with no plans to initiate HAART within the next 12 weeks NOTE: \* A non-HAART regimen is considered to be a therapy that does not include a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor~* No untreated invasive cancer of the lower genital tract~* No concurrent neoplasia requiring cytotoxic therapy~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Life expectancy ≥ 3 months~* Hemoglobin ≥ 8 g/dL~* ANC ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Creatinine \< 1.5 times upper limit of normal (ULN)~* Total or conjugated (direct) bilirubin ≤ 2.5 times ULN~* AST and ALT ≤ 3 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* No acute, opportunistic infection other than oral thrush, yeast vaginitis, or genital herpes within the past 14 days~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior ablative or surgical treatment of perianal dysplasia~* At least 4 weeks since prior topical treatment for perianal dysplasia~  * If any prior treatment caused significant trauma to ther area, healing should occur prior to starting treatment~* More than 14 days since prior acute treatment for infection (other than for oral thrush, yeast vaginitis, or genital herpes) or other serious medical illness~* No concurrent corticosteroids other than replacement doses~* No other concurrent investigational drugs except IND-approved anti-retroviral agents~* No concurrent systemic cytotoxic chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cidofovir (Type: EXPERIMENTAL): 1.0% topical cidofovir cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with confirmed infection by SARS-CoV-2~* Hyperglycemia higher than 140 mg/dl~* Patients accepting oral medications~* Both sex~* Older than 18 years of age~* Patients who accept to participate in the study and sign the consent form~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy~* Hyperosmolar hyperglycemic state or diabetic ketoacidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DPP4 inhibitor + insulin (Type: EXPERIMENTAL): Patients assigned to this group of treatment will receive Linagliptin 5mg orally once daily plus a basal-bolo insulin scheme
- Insulin scheme alone (Type: ACTIVE_COMPARATOR): Patients assigned to this group will receive only a basal-bolus insulin scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* Diagnosed with type 2 diabetes mellitus~* The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study~* Male or female, age above or equal to 18 years at the time of signing informed consent~* Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit'(V1) if in line with local clinical practice~* Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Treatment with any investigational drug within 30 days prior to enrolment into the study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Patients with type 2 diabetes (Type: None): Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minimum Effective Volume of Local Anesthetic Using Ultrasound for Brachial Plexus Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving interscalene brachial plexus block for shoulder surgery~* Age between 21 and 65 years~* ASA physical status I/II~* Body mass index \< 35 kg/m2~Exclusion Criteria:~* Chronic obstructive pulmonary disease~* Psychiatric history~* Allergy to bupivacaine~* Infection in the site of block~* Coagulation disorders

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Astral VAPS AutoEPAP Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for the study are:~1. Participant has ability to provide written informed consent~2. Participants aged ≥18 years old~3. Participant has documented respiratory failure (e.g. sleep hypoventilation with historical PtCO2 increase ≥ 10mmHg) and/or daytime hypercapnia (\>45 mmHg)~4. Participant is currently using non-invasive positive pressure ventilation in ST or VAPS mode for ≥ 3 months~5. Participants with a previously documented AHI ≥ 5/hr~6. Participants with a recently (≤ 12 months ago) reviewed EPAP setting~Exclusion criteria for the study are:~1. Participants are not compliant on NIPPV (e.g. \< 4 hr/night)~2. Participants who are pregnant~3. Participants on oxygen therapy ≥5 L/min~4. Participants with an invasive interface (e.g. tracheostomy)~5. Participants who have had an acute exacerbation within the last 3 months that resulted in a hospitalisation~6. Participants who are acutely ill, medically complicated or who are medically unstable~7. Participants in whom NIPPV therapy is otherwise medically contraindicated~8. Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days~9. Participants with untreated, non-OSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome.~10. Participants who have the following pre-existing conditions: severe bullous lung disease, recurrent pneumothorax or pneumomediastinum, cerebrospinal fluid leak, recent cranial surgery or trauma.~11. Participant does not comprehend English~12. Participant is unable or unwilling to provide written informed consent~13. Participant is physically and/or mentally unable to comply with the protocol~14. Participant is not suitable to participate in the trial for any other reason in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iVAPS with AutoEPAP (Type: EXPERIMENTAL): This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
- iVAPS with manual EPAP (Type: ACTIVE_COMPARATOR): This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pancreatic exocrine insufficiency has to be proven (in medical history) by the following criteria:~* Direct or indirect pancreatic function test (except stool fat excretion) or Clinical signs of severe steatorrhoea that resolved upon administration of pancreatic supplementation.~* Total stool fat \> 40 g over 4 days (using Van De Kamer method)~* Proven chronic pancreatitis~* Females of child-bearing potential must agree to continue using a medically acceptable method of birth control~Exclusion Criteria:~* Ileus or acute abdomen~* Any type of malignancy involving the digestive tract in the last 5 years~* Presence of pseudo-pancreatic cyst ≥ 4~* Continued excessive intake of alcohol or drug abuse~* Known infection with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index \>= 25 kg/m2~* Body Weight \> 50 kg~* Liver fat (assessed via MRI-PDFF) \>= 8%~* Biopsy-proven NASH - diagnosed in previous 24-months~* Presumed NASH - per Sponsor's definition~* NAFLD with minimal inflammation/fibrosis~* Features of Metabolic Syndrome~Exclusion Criteria:~* Alcohol-induced steatohepatitis or other forms of chronic liver disease~* Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus~* Severe Renal Impairment~* Contraindications for MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Double-Blind, PF-05221304-matching Placebo
- PF-05221304 - 2 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 2 mg, once-daily
- PF-05221304 - 10 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 10 mg, once-daily
- PF-05221304 - 25 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 25 mg, once-daily
- PF-05221304 - 50 mg (Type: ACTIVE_COMPARATOR): PF-05221304 - 50 mg, once-daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~Patients:~* Receive care at the Geisinger Danville Nephrology Clinic~* Age ≥ 18 years~* eGFR ≤ 25 mL/min/1.73 m and 2-year kidney failure risk score \>10% based on kidney failure risk equation, or nephrologist recommendation for vascular access~* Participation in the Vascular Access Navigation and Education Quality Improvement Program~Providers: Professional involved in dialysis vascular access care (e.g., nephrologist, surgeon, kidney disease clinic nurse, etc.) at Geisinger in Danville, PA~Exclusion Criteria~Patients:~* Too far into the vascular access creation process to benefit from the intervention (e.g. completed vascular access surgery appointment or has a surgery appointment scheduled within the next 4 weeks),~* Inability to consent, or~* Inability to complete interviews in English~Providers: None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vascular access quality improvement program participants (Type: EXPERIMENTAL): All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhotic patients who were admitted between January 2010 and December 2018.~2. A diagnosis of acute gastrointestinal bleeding.~3. Patients who received terlipressin or somatostatin/octreotide.~4. Age or sex was not limited.~5. Use of endoscopy was not limited.~6. Comorbidity was not limited.~7. Malignancy was not limited.~Exclusion Criteria:~1. Renal parenchymal diseases.~2. Absence of baseline serum creatinine.~3. Absence of serum creatinine 3-5 days after terlipressin or somatostatin/octreotide.~4. Duration of terlipressin or somatostatin/octreotide was less 3 days.~5. Patients who underwent transjugular intrahepatic portosystemic shunt.~6. Patients who underwent surgical shunt, splenectomy with or without devascularization, or liver transplantation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin group (Type: None): Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
- Somatostatin/Octreotide group (Type: None): Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete